This is not the most recent version of the article. View current version (13 MAY 2014)

Intervention Protocol

Pericyazine for schizophrenia

  1. Hosam E Matar1,*,
  2. Muhammad Qutayba Almerie2,
  3. Samer Makhoul3,
  4. Pamela Humphreys4,
  5. Ichiro M Omori5

Editorial Group: Cochrane Schizophrenia Group

Published Online: 8 OCT 2008

Assessed as up-to-date: 29 JUL 2008

DOI: 10.1002/14651858.CD007479


How to Cite

Matar HE, Almerie MQ, Makhoul S, Humphreys P, Omori IM. Pericyazine for schizophrenia (Protocol). Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD007479. DOI: 10.1002/14651858.CD007479.

Author Information

  1. 1

    Sheffield Teaching Hospitals, Sheffield, UK

  2. 2

    National Collaborating Centre for Women's & Children's Health, London, UK

  3. 3

    TEWV, General Adult Psychiatry & Addictions, Easington, UK

  4. 4

    Glyndwr University, Wrexham, UK

  5. 5

    Toyokawa City Hospital, Department of Psychiatry, Aichi, Japan

*Hosam E Matar, Sheffield Teaching Hospitals, Sheffield, UK. hematar@doctors.org.uk. MatarH@Cardiff.ac.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 8 OCT 2008

SEARCH

This is not the most recent version of the article. View current version (13 MAY 2014)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To evaluate the clinical effects and safety of pericyazine in comparison with placebo, typical and atypical antipsychotic agents and standard care for people with schizophrenia.